Dow Inc.
DOW
$32.35
-1.67%
Dow Inc. is a diversified global chemicals producer, formed in 2019 from the DowDuPont merger, and a leading manufacturer of polyethylene, ethylene oxide, silicone rubber, and other specialty chemicals used across consumer and industrial end markets. As one of the largest chemical companies in the world, Dow holds a dominant position in packaging, infrastructure, and performance materials, leveraging its scale and integrated supply chain to compete globally. The current investor narrative centers on the company's recovery from a severe downturn exacerbated by Middle East supply chain disruptions, with management guiding to improved Q2 results and ongoing cost-saving initiatives. Recent headlines highlight the impact of the Strait of Hormuz closure on petrochemical prices and margins, while the stock has rebounded strongly over the past year, reflecting optimism about a cyclical recovery and the company's ability to navigate geopolitical risks.…
DOW
Dow Inc.
$32.35
Related headlines
Investment Opinion: Should I buy DOW Today?
We rate Dow as a Hold, with a thesis that the stock is a value play with a high dividend yield, but the recovery is uncertain and the upside is limited. The analyst consensus is Buy with an average target of $35.69, implying 10.3% upside, which is modest given the risks. The stock is trading at a PS ratio of 0.42x, far below its historical average, and a PB ratio of 1.04x, suggesting it is undervalued on a historical basis. However, the negative EPS and thin margins indicate that the company is not yet profitable, and the forward PE of 17.8x is based on estimated EPS of $1.95, which may be optimistic.
Sign up to view all
DOW 12-Month Price Forecast
The AI assessment is neutral, reflecting the balance between deep value and operational challenges. The historically low valuation provides a margin of safety, but the negative earnings and high debt limit upside. The stock's low beta suggests it is defensive, but it also means it may underperform in a strong bull market. The key factor to watch is whether Q2 earnings show a clear inflection point; if margins expand significantly, the stance would upgrade to bullish. Conversely, if the company cuts its dividend or guidance disappoints, the stance would turn bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Dow Inc.'s 12-month outlook, with a consensus price target around $35.69 and implied upside of +10.3% versus the current price.
Average Target
$35.69
0 analysts
Implied Upside
+10.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$29 - $48
Analyst target range
The consensus target of $35.69 implies a 10.3% upside from the current price, which is modest and suggests that the stock is fairly valued near its current levels. The recommendation mean of 2.39 leans toward 'Buy' but is not overwhelmingly bullish, reflecting the challenges the company faces. The estimated EPS for the next fiscal year is $1.95 on average, which would represent a significant turnaround from the current losses, but the low estimate of $1.70 and high of $2.27 show a wide range of expectations. Overall, the analyst community sees Dow as a recovery play with balanced risk-reward, but the wide target range highlights the uncertainty in the chemicals sector.
Bulls vs Bears: DOW Investment Factors
Dow presents a classic cyclical recovery play with deeply depressed valuations and a high dividend yield, but the bear case is anchored by persistent losses, high debt, and geopolitical risks. Currently, the bull case has slightly stronger evidence due to the historically low valuation and positive Q2 guidance, but the outcome hinges on the speed of the petrochemical supply chain recovery. The most critical tension is whether the company can translate improving demand into sustainable profitability, as margins remain razor-thin and any setback could push the stock back toward its 52-week low.
Bullish
- Historically Low Valuation: PS ratio of 0.42x is at the bottom of its historical range (1.6x-3.8x), and PB ratio of 1.04x is near the lower end (0.93x-3.04x). This suggests the market is pricing in significant pessimism, offering potential upside if earnings recover.
- Strong Relative Strength: Stock is up 36.6% over the past year, outperforming the S&P 500's 20.5% gain. Relative strength of 16.1% over 1 year indicates positive momentum and investor confidence in the recovery story.
- Positive Q2 Guidance: Despite Q1 revenue miss and widening loss, management guided to improved Q2 results. This optimism, combined with cost-saving initiatives, suggests the worst may be over and earnings could rebound.
- High Dividend Yield: Dividend yield of 8.96% is exceptionally high, providing a substantial income cushion while waiting for earnings recovery. The company maintains a 114-year dividend streak, signaling financial resilience.
Bearish
- Negative Earnings and Margins: TTM EPS is -$0.16, with a net margin of -6.6% and operating margin of 0.65%. ROE is -16.4%, reflecting persistent losses and poor profitability, which could continue if the recovery stalls.
- High Debt and Negative FCF: Debt-to-equity ratio of 1.22 is elevated, and TTM free cash flow is -$1.395 billion. While Q1 2026 FCF was positive at $621 million, the overall trend raises concerns about financial flexibility.
- Geopolitical Supply Chain Risks: The Strait of Hormuz closure disrupted petrochemical supply chains, causing Q1 revenue miss and widening losses. CEO warned the shock could take 275 days to clear, implying prolonged margin pressure.
- Modest Analyst Upside: Average target price of $35.69 implies only 10.3% upside, which is modest. The wide range ($29-$48) reflects high uncertainty, and the low target suggests potential downside to $29.
DOW Technical Analysis
Key support is at the 52-week low of $20.65, while resistance is at the 52-week high of $42.74. A breakout above $42.74 would signal a resumption of the uptrend and could lead to further gains, while a breakdown below $20.65 would indicate a bearish reversal. The stock's beta of 0.423 suggests it is less volatile than the market, which is typical for a large-cap chemical company, but it also means that during market selloffs, Dow may decline less than the broader market. The recent price action shows the stock consolidating between $29 and $33, with volume averaging around 9.18 million shares, indicating a period of indecision.
Beta
0.42
0.42x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$21-$43
Price range past year
Annual Return
+36.6%
Cumulative gain past year
| Period | DOW Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | +3.6% |
| 3m | -10.2% | +2.7% |
| 6m | +6.0% | +11.4% |
| 1y | +36.6% | +18.7% |
| ytd | +33.3% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOW Fundamental Analysis
Dow's balance sheet shows a debt-to-equity ratio of 1.22, which is relatively high, and the company had negative free cash flow of -$1.395 billion on a trailing twelve-month basis. In Q1 2026, operating cash flow was $1.124 billion, but capital expenditures of $503 million resulted in positive free cash flow of $621 million for the quarter. The current ratio of 1.97 indicates adequate liquidity, and the company has $4.235 billion in cash. However, the high debt load and negative FCF over the past year raise concerns about financial flexibility, especially if the downturn persists. Return on equity is negative at -16.39%, reflecting the losses, while return on assets is a meager 1.3%.
Quarterly Revenue
$9.8B
2026-03
Revenue YoY Growth
-6.1%
YoY Comparison
Gross Margin
6.5%
Latest Quarter
Free Cash Flow
$-1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOW Overvalued?
Historically, Dow's PS ratio has ranged from about 1.6x to 3.8x over the past few years, with the current 0.42x being at the very bottom of that range. This suggests that the stock is trading at a historically low valuation relative to sales, which could indicate a value opportunity if the company's earnings recover. However, it also reflects the market's skepticism about the sustainability of current revenue levels and the potential for further deterioration. The PB ratio of 1.04x is also near the lower end of its historical range of 0.93x to 3.04x, reinforcing the value proposition.
PE
-6.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant, with a debt-to-equity ratio of 1.22 and negative TTM free cash flow of -$1.395 billion. While Q1 2026 showed positive FCF of $621 million, the company's high interest expenses ($219 million in Q1) and negative ROE (-16.4%) indicate that the balance sheet is under stress. If the downturn persists, Dow may face liquidity constraints, potentially forcing dividend cuts or asset sales to service debt. The current ratio of 1.97 provides some buffer, but the negative net margin of -6.6% suggests that operational losses are eroding cash reserves.
FAQ
The key risks are: 1) Financial risk from high debt (debt-to-equity of 1.22) and negative free cash flow (-$1.395 billion TTM), which could lead to dividend cuts or financial distress. 2) Geopolitical risk from Middle East supply chain disruptions, as seen in Q1 2026, which can cause revenue misses and margin compression. 3) Competitive risk from low-cost producers, especially in the Middle East, which could keep margins thin. 4) Macro risk from a global economic slowdown, which would reduce demand for chemicals. The most severe risk is a prolonged supply chain disruption, which could push the stock down to $20.65, a -36% decline from current levels.
The 12-month forecast is a base case with a 50% probability of the stock trading between $33 and $37, aligning with the analyst average target of $35.69. The bull case (30% probability) sees the stock reaching $40-$48 if the recovery accelerates, while the bear case (20% probability) could see it fall to $25-$29 if the downturn persists. The most likely scenario is a gradual recovery, with the stock trading near its current level of $32.35. The key assumption is that the petrochemical supply chain normalizes and margins improve, leading to EPS of $1.95. If this does not happen, the stock could underperform.
DOW is undervalued relative to its own history, with a PS ratio of 0.42x versus a historical range of 1.6x-3.8x, and a PB ratio of 1.04x versus a range of 0.93x-3.04x. This suggests the market is pricing in a prolonged downturn. However, the forward PE of 17.8x is not cheap, and the EV/EBITDA of 27.3x is high due to depressed EBITDA. The market is expecting a significant earnings recovery, as indicated by the estimated EPS of $1.95 for next year. If the recovery fails to materialize, the stock could be fairly valued or even overvalued. Overall, the valuation is attractive for value investors, but it reflects the high risk of the cyclical business.
DOW offers a high dividend yield of 8.96% and trades at historically low valuations, with a PS ratio of 0.42x and PB ratio of 1.04x. However, the company is currently unprofitable, with negative EPS and a net margin of -6.6%. Analysts see a modest 10.3% upside to the average target of $35.69, but the wide range ($29-$48) reflects high uncertainty. For income investors willing to wait for a cyclical recovery, DOW could be a good buy at current levels, but for growth investors, the lack of earnings momentum is a concern. The stock is a better buy if you believe the petrochemical supply chain will normalize and margins will recover.
DOW is more suitable for long-term investment, given its cyclical nature and the current recovery phase. The stock has a beta of 0.423, indicating low volatility, and offers a high dividend yield, which can provide income while waiting for the cycle to turn. Short-term trading is possible, but the stock's price movements are heavily influenced by geopolitical events and commodity prices, making it unpredictable. A minimum holding period of 3-5 years is recommended to ride out the cyclical downturn and benefit from the eventual recovery. The company's 114-year dividend streak suggests a commitment to returning capital, but the payout ratio of -56.8% indicates the dividend is not covered by earnings, so a cut is possible if the downturn persists.